

## ETHICS COMMITTEE / IRB APPROVAL LETTER

**From:** National Healthcare Group Domain Specific Review Board  
**To:** Dr. Wei Zhang  
**Reference Number:** NHG-DSRB-2024-0301  
**Date:** 2024-04-01  
**Protocol:** NVX-1218.22 -- NovaPlex-450 in Advanced NSCLC  
**Amendment:** N/A -- Initial Approval

## Initial Approval

Dear Dr. Wei Zhang,

The National Healthcare Group Domain Specific Review Board is pleased to confirm approval of the above-referenced clinical study at your institution. This approval is effective from 2024-04-01 and is valid for 12 months.

This approval covers:

- Protocol Version 1.0 (dated 2023-12-01)
- Informed Consent Form Version 1.0 (dated 2023-12-01)
- Patient recruitment materials as submitted

Conditions of approval:

1. Any protocol amendments must be submitted for review prior to implementation
2. Annual progress reports must be submitted
3. All serious adverse events must be reported within 7 days
4. The study must be conducted in accordance with ICH GCP E6(R2) guidelines

## Approval Details

**Status:** APPROVED  
**Approval Date:** 2024-04-01  
**Expiry Date:** 2025-01-14  
**Renewal Required:** Yes -- submit renewal 60 days before expiry

**Chairperson Signature:**

---

IRB Chairperson